key: cord-0976163-yi7o2zl5
authors: Pradenas, Edwards; Trinité, Benjamin; Urrea, Víctor; Marfil, Silvia; Ávila-Nieto, Carlos; Rodríguez de la Concepción, María Luisa; Tarrés-Freixas, Ferran; Pérez-Yanes, Silvia; Rovirosa, Carla; Ainsua-Enrich, Erola; Rodon, Jordi; Vergara-Alert, Júlia; Segalés, Joaquim; Guallar, Victor; Valencia, Alfonso; Izquierdo-Useros, Nuria; Paredes, Roger; Mateu, Lourdes; Chamorro, Anna; Massanella, Marta; Carrillo, Jorge; Clotet, Bonaventura; Blanco, Julià
title: Stable neutralizing antibody levels six months after mild and severe COVID-19 episode
date: 2021-01-31
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.01.005
sha: d8cd2197a2512a868fde1a7a19d63d4b00f168c9
doc_id: 976163
cord_uid: yi7o2zl5

Background Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. Methods We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for more than 6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD) and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. Findings We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted six months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a two-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at six months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2 or NP antibody titers, all of them showing a constant decline over the follow-up period. Conclusions Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage. Funding This study was funded by Grifols, CERCA Programme and Departament de Salut (Generalitat de Catalunya), Spanish Health Institute Carlos III, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat and Correos.

While the early humoral response after SARS-CoV-2 infection has been thoroughly described [1] [2] [3] [4] [5] , current data on the decay of antibody levels beyond the convalescent stage depict a heterogeneous scenario with limited information on the neutralizing activity throughout the follow-up period [6] [7] [8] . Various authors have recently suggested more complex kinetics of neutralizing activity decay as compared to total antibody titers, with clonotype-, epitope-, or subject-specific patterns that evolve in terms of potency and resistance to epitope mutations [9] [10] [11] . In this study, we longitudinally evaluated the neutralizing humoral response, in mild/asymptomatic and hospitalized individuals infected by SARS-CoV-2, over a 6-month period. These mid-term kinetics showed in both groups, a stable behavior of the neutralizing response despite a clear decrease of the total viral specific humoral response.

Our analysis included 210 patients with RT-PCR-confirmed SARS-CoV-2 infection, recruited during the first and second waves of the COVID-19 epidemic in Catalonia (North-East Spain). Of them, 106 (50.5%) had a mild or asymptomatic infection, and 104 (49.5%) required hospitalization because of respiratory compromise ( Table 1) . As reported in our country 12 , the hospitalization group showed significantly older age and lower frequency of female (Table 1) . We collected samples periodically throughout a maximum follow-up period of 242 days (mean follow-up timepoint of patients from the first COVID-19 wave was 201 days, Figure S1 ). Most study participants developed a neutralizing humoral response against SARS-CoV-2 HIV-based pseudoviruses, that was confirmed using infectious viruses 13 . However, in line with trends reported elsewhere 6, 8 , mildly affected or asymptomatic individuals developed a 10-fold lower maximal neutralization titer than those who required hospitalization when the full dataset was analyzed (p<0.0001, Mann-Whitney test; Fig. 1a ). The higher number of determinations obtained from hospitalized individuals during the acute phase permitted the clear observation of a sharp initial response (Fig. 1b-c) , also reported in previous analyses of the early response [1] [2] [3] [4] [5] . This was visible for individuals recruited during both the first (March-June 2020) and the second (July-October 2020) waves of COVID-19 pandemic in Catalonia. A longitudinal analysis fitted to a four-parameter logistic model of increase defined a 30-day sharpening phase after symptom onset, irrespective of the wave in which hospital admission occurred. Half maximal neutralization activity was achieved on day 10 (95% confidence interval, CI 8-11); 80% maximal response, which corresponded to 3.97 logs (i.e., 9,333 reciprocal dilution), was achieved on day 14 (Fig. J o u r n a l P r e -p r o o f 1d). Moreover, as reported previously using an infectious virus neutralization assay 13 , we could not find gender impact on the elicitation of neutralizing antibodies in hospitalized individuals. Based on these findings, irrespective of gender and wave, we decided to set day 30 after symptom onset as a starting point for the longitudinal analysis of immune response at the mid-term.

The longitudinal modeling of the neutralizing activity at mid-term in our cohort revealed a nearly flat slope (i.e., not significantly different from 0, with half-life 2134 days) in individuals with asymptomatic infection or mild disease (Fig. 2a) . Conversely, the decrease of neutralizing activity in hospitalized individuals showed a two-phase pattern, with a rapid decay (half-life 31 days) until day 80 that slowed down to a flat slope (half-life 753 days) from that time point on (Fig. 2b ). In agreement with previous data, suggesting faster decay of neutralizing antibodies in male compared to female infected individuals 9,14 , we found significant gender differences in early decay; however, upon stabilization of neutralization titers after day 80, no gender impact was observed in our cohort ( Figure S2 ). Fig. 2d ). Although this number must be taken cautiously due to the cut-off assumption, our finding suggests that hospitalized patients have a higher capacity for long-term neutralization, despite the faster initial decay in neutralization activity.

It has recently been proposed that the kinetics of neutralizing activity may not mirror those of antibody titers 11 . Hence, we investigated the change in IgG titers in a subset of 28 individuals (14 in each severity group) with the most extended follow-up period. The analysis included antibodies against the S-protein receptor-binding domain (RBD), the main target of SARS-CoV-2 specific neutralizing antibodies 16 ; the S2 subunit of the S protein, that may also contribute to neutralizing activity and are more cross-reactive with other coronaviruses 17 ; and the nucleoprotein (NP), which are very abundant, albeit J o u r n a l P r e -p r o o f unable to neutralize the SARS-CoV-2 16 . The longitudinal analysis revealed a one-phase significant (p<0.0001) steady decay pattern of all tested antibodies, which was notably faster in anti-NP IgG (Fig. 3a-c) . The half-life of anti-RBD, anti-S2, and anti-NP antibodies for the period beyond day 30 were 86, 108, and 59 days, respectively. These values were consistent with those reported by Wheatley et al., estimated on a 160-day time frame 11 . Although the limited sample size of this sub-analysis precluded independent modeling of the decay in mild/asymptomatic and hospitalized patients, the latter showed significantly higher titers of anti-S2 at the end of the follow-up period ( Figure S3 ), whereas no significant differences were found in other antibodies regarding disease status. Interestingly, in this subset of individuals, the decay in antibody titers contrasted with the behavior of neutralizing activity, which fitted to a two-phase model-as in the whole dataset-with a rapid decay until day 80 (slope 0.014, half-life 22 days) and a flat slope (i.e., not significantly different from 0) afterward (Fig. 3d ).

Complementary data on the binding affinity and B-cell clone abundance at the same time points would provide a more comprehensive picture to explain this divergent trend.

However, our findings support the hypothesis of Gaebler et al., who suggested that the accumulation of IgG somatic mutations-and subsequent production of antibodies with increased neutralizing potency-allow the maintenance of neutralizing activity levels, despite the decline in specific antibody titers 10 . Of note, our follow-up period encompassed two waves of the COVID-19 outbreak in our country. Individuals infected during the first wave were likely to be exposed to high viral pressure in their environment, potentially favoring further virus exposure that may also contribute to maintaining humoral responses, adding to the mechanism proposed by Gaebler et al 10 .

Our longitudinal analysis supplements current evidence regarding mid-term immunity against SARS-CoV-2 8,10,11 and confirms the slow decay and mid-term maintenance of neutralizing activity observed in other cohorts with a 5-to-11% prevalence of hospitalized patients 8, 10 . In this regard, the two-phase behavioral pattern of neutralizing activity observed in hospitalized individuals suggests that the rapid decay reported in previous characterizations 7 might be due to the abundance of individuals in this early phase. Furthermore, apparent inconsistencies found between the declines of neutralizing activity and IgG titers reinforce the idea proposed by other authors that the behavior of antibody titers may not mirror the neutralizing activity. Interestingly, differences in decline were not only observed between neutralizing activity and anti-N antibodies, which do not contribute to neutralization, but also for anti-S2 and anti-RBD antibodies, which are major determinants of neutralization 16, 17 . Taken together, current evidence on immunity to SARS-CoV-2 infection suggests stability of neutralizing activity, pointing towards an optimistic scenario for the establishment of infection-or vaccine-mediated herd immunity. Still, long-term data available on other human coronaviruses show waning of antibodies 1-to-2 years after infection 18, 19 , with uncertainty regarding the immune response behavior in the context of vaccine-mediated immunity 20 . The continuity of our prospective cohort of individuals recovered from SARS-CoV-2 infection will provide novel insights into the long-term kinetics of the immune response.

Our analysis is limited by the reduced sample size, particularly in the acute phase for mild/asymptomatic subgroup, for which we failed to define the kinetics of neutralizing response development and to identify a two-phase pattern decay. Despite the limited 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Julià Blanco (jblanco@irsicaixa.es).

The plasmid pcDNA3.4 SARS-CoV-2.Sct∆19 is available upon request to the lead contact.

This study did not generate any unique datasets or code.

The study was approved by the Hospital Ethics Committee Board from Hospital 

The humoral response against SARS-CoV-2 was evaluated with an in-house sandwich-ELISA using the following antigens (Sino Biological, Germany): S2 (Ser686-Pro1213), nucleocapsid protein (NP), which is unrelated to neutralizing capacity. Nunc MaxiSorp plates were coated with 50 µL of anti-6x-His antibody clone HIS.H8 (2 µg/mL, Thermo

Fisher Scientific) in PBS overnight at 4ºC. After washing, plates were blocked with 1% BSA in PBS (Miltenyi Biotec, Germany) for two hours at room temperature. Antigens were added at 1 µg/mL concentration (50 µL/well) and incubated overnight at 4ºC.

Plasma samples were heat-inactivated before use (56ºC for 30 minutes) and analyzed in duplicate in antigen-coated and antigen-free wells in the same plate. Serial dilutions of a positive plasma sample were used as standard. A pool of pre-pandemic plasmas from healthy controls was used as a negative control. Standards, negative control, and plasma samples were diluted in blocking buffer and were incubated (50 µL/well) for one hour at room temperature. The HRP-conjugated (Fab)2 goat anti-human IgG (Fc specific, Jackson ImmunoResearch, UK) was then incubated for 30 minutes at room temperature.

Plates were revealed with o-Phenylenediamine dihydrochloride (Sigma-Aldrich, USA) and reaction was stopped using 4N of H 2 SO 4 (Sigma-Aldrich). Optical density (OD) at 492 nm with noise correction at 620 nm were used to calculate specific signal for each antigen after subtracting the antigen-free well signal for each sample. Standard curves were fitted to a 5-parameter logistic curve and data was expressed as arbitrary units (AU) according to the standard.

HIV reporter pseudoviruses expressing SARS-CoV-2 S protein and Luciferase were Mixed-effects models were fitted using "nlme" R package.

• Neutralizing activity against SARS-CoV-2 is maintained for at least 6 months 

Assessing the durability of neutralizing responses against SARS-CoV-2 is crucial to predict the level of protection in post-convalescent COVID-19 patients. We monitored for more than six months a cohort of 210 SARS-CoV-2 infected individuals with a wide range of symptoms (from asymptomatic infection to severe disease). Our results indicate that neutralizing antibodies are stable for at least six months after infection. However, individuals with mild or asymptomatic infection developed lower titers of neutralizing antibodies, and could be at higher risk of reinfection. Despite the maintenance of neutralizing antibodies, total antibody titers slowly but gradually declined overtime without apparent stabilization. This observation requires further analysis to evaluate the potential role of viral persistence or viral re-exposure in maintaining neutralization titers. 

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

Profile of specific antibodies to SARS-CoV-2: The first report

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv

Evolution of immunity to SARS-CoV-2. medRxiv

Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Sex differences in the decline of neutralizing antibodies to SARS-CoV-2

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Duration of antibody responses after severe acute respiratory syndrome

The time course of the immune response to experimental coronavirus infection of man

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection (2020). A minimal common outcome measure set for COVID-19 clinical research

Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

A cellto-cell HIV transfer assay identifies humoral responses with broad neutralization activity